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AbstrAct
The Notch/CSL pathway plays an important role in skin homeostasis and 
carcinogenesis. CSL, the key effector of canonical Notch signaling endowed with an 
intrinsic transcription repressive function, suppresses stromal fibroblast senescence 
and Cancer Associated Fibroblast (CAF) activation through direct down-modulation 
of key effector genes. Interacting proteins that participate with CSL in this context 
are as yet to be identified. We report here that Programmed Cell Death 4 (PDCD4), a 
nuclear/cytoplasmic shuttling protein with multiple functions, associates with CSL and 
plays a similar role in suppressing dermal fibroblast senescence and CAF activation. 
Like CSL, PDCD4 is down-regulated in stromal fibroblasts of premalignant skin actinic 
keratosis (AKs) lesions and squamous cell carcinoma (SCC). While devoid of intrinsic 
DNA binding capability, PDCD4 is present at CSL binding sites of CAF marker genes as 
well as canonical Notch/CSL targets and suppresses expression of these genes in a 
fibroblast-specific manner. Thus, we propose that PDCD4 is part of the CSL repressive 
complex involved in negative control of stromal fibroblasts conversion into CAFs.
INtrODUctION
Notch/CSL signaling is an important form of cell-
cell communication with an established pro-differentiation 
and tumor suppressing function in the epidermal 
compartment of the skin [1]. This pathway plays also an 
important role in the dermal compartment. In particular, 
deletion or silencing of the CSL gene in dermal fibroblasts, 
of both mouse and human origin, results in activation 
of a CAF phenotype, with expression of mitogenic and 
pro-inflammatory cytokines and in vivo induction of 
keratinocyte tumor formation [2]. More recent work has 
shown that loss of CSL signaling in dermal fibroblasts 
results also in impaired proliferation and senescence, 
providing a molecular underpinning to previous findings 
that senescence of stromal cells and activation of a CAF 
phenotype are closely associated events [3]. 
CSL is the key mediator of canonical Notch 
activation at the level of transcription [4]. Under basal 
conditions, CSL functions as a repressor of transcription 
in association with co-repressors like nCor1/nCor2, 
SMART, histone deacetylase (HDACs) and Skip. Nuclear 
translocation and physical binding of the activated 
Notch intracellular domain (NICD) converts CSL from a 
transcription repressor to an activator, replacing associated 
co-repressors with co-activators like Mastermind-like 
(MAML) proteins and histone acetylases (HATs) [5]. 
Components of these classical CSL co-repressor and 
co-activator complexes have been extensively studied at 
both functional and ultra-structural/molecular levels [6]. 
Another CSL-interacting protein called RBPj-interacting 
and tubulin associated (RITA) has also been identified 
that act as a negative modulator of Notch/CSL signaling 
through a different mechanism, i.e. promoting CSL export 
from the nucleus [7]. Additional CSL-interacting proteins 
are likely to exist, which may play an important role in 
both canonical and non-canonical Notch signaling and 
other cell type-specific CSL functions. 
PDCD4 is known as a pro-apoptotic and tumor-
suppressing gene [8, 9]. Over-expression of PDCD4 
inhibits tumor growth and metastasis [10], whereas 
PDCD4 knockout mice develop spontaneous tumors 
(lymphomas) [11]. Biochemically, PDCD4 can function 
as an inhibitor of mRNA translation of specific target 
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genes by interacting with the eukaryotic initiation 
factor 4A (eIF4A) and suppressing its function [12]. In 
this context, mucin 1 (MUC1), an oncoprotein that is 
aberrantly expressed in human cancers, is a translational 
target of PDCD4 [13], suggesting that PDCD4 acts as a 
tumor suppressor by inhibiting oncoprotein translation. 
However, PDCD4 can also affect gene transcription. For 
instance, it has been reported to modulate c-Jun activity 
by interacting and blocking its phosphorylation, thus 
inhibiting AP-1 dependent transcription [14]. PDCD4 can 
also interact directly with the transcription factor Twist1, 
a key regulator of CAFs [15], interfering with its DNA 
binding [16]. PDCD4 mRNA is down-regulated by miR-
21, and miR-21-mediated PDCD4 suppression is required 
for the survival of Notch-driven T-cell leukemia [17]. Of 
relevance for the present study, PDCD4 down-regulation 
by TGF-β-induced miR-21 induction was also implicated 
in up-regulation of the CAF marker αSMA through as yet 
unidentified mechanisms in differentiating myofibroblasts 
[18]. 
We report here that PDCD4 is a novel CSL 
interactor of functional relevance in human dermal 
fibroblasts (HDFs). Silencing of PDCD4 in these cells 
reproduces the effects of loss of CSL, leading to induction 
of cellular senescence and conversion into CAFs with 
tumor enhancing properties. While devoid of intrinsic 
DNA binding activity, PDCD4 is found at the promoter 
regions of Notch/CSL target genes and controls expression 
of these genes in a fibroblast-specific manner. Overall, 
the findings indicate that PDCD4 is part of the CSL 
repressive complex involved in negative control of stromal 
fibroblasts to CAF conversion.
rEsULts
Endogenous interaction of PDcD4 with csL
Screening of a yeast two-hybrid cDNA library with 
a CSL bait pointed to PDCD4 as a potential interactor. No 
direct binding was detected after over-expression of the 
two proteins in an exogenous system. However, a weak 
but consistent association between endogenous PDCD4 
and CSL was found by co-immunoprecipitation assays 
with nuclear extracts derived from HDFs (Figure 1A). 
For independent confirmation, we performed proximity 
ligation assays (PLA) for detection and localization of 
protein-protein interactions. Positive punctate signals 
Figure 1: Endogenous PDcD4/csL association and co-localization. A. Nuclear extracts from early passage HDFs were analyzed 
by immune-precipitation (IP) with anti-PDCD4 antibodies or non-immune IgGs followed by immunoblotting with antibodies against CSL 
or PDCD4 as indicated. Shown are the results of two different experiments with HDF strains of independent origin. b. Proximity ligation 
assay (PLA) were used for in situ detection of CSL-PDCD4 association in HDFs. Red fluorescence foci (PLA signals) represent the 
interaction between CSL and PDCD4, and were analyzed by confocal microscopy with DAPI staining of nuclei (blue). The specificity of 
CSL-PDCD4 PLA signals was confirmed by the significant reduction of PLA signal in HDFs with siRNA-mediated CSL gene silencing. 
Shown are representative PLA images and the average number of dots per nucleus in HDFs plus/minus siRNA-mediated CSL gene 
silencing. PLA dots were counted from at least 30 cells in four fields. *p < 0.001, two-tailed t-test. c. Double immunofluorescence analysis 
of HDFs with anti-CSL (green) and anti-PDCD4 (red) antibodies and DAPI for nuclear DNA staining (blue). Images are representative of 
three independent experiments with two different strains of HDFs. Bar, 10μm.
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resulting from the close juxtaposition of the antibodies 
were found in HDFs, with > 6 folds reduction in HDFs 
with CSL gene silencing as control of specificity (Figure 
1B). Nuclear co-localization of the two proteins was also 
observed by double immunofluorescence analysis of 
HDFs (Figure 1C). 
PDcD4 gene silencing reproduces the effects of 
csL loss in induction of cAF markers and Notch 
target genes
CSL gene silencing in HDFs leads to premature 
senescence together with acquisition of a CAF phenotype 
[3]. Similarly, PDCD4 gene silencing triggered cellular 
senescence, as assessed by reduced clonogenecity (Figure 
2A) and increased Senescence Associate β-galactosidase 
(SA β-gal) (Figure 2B), and resulted in the concomitant 
induction of senescence- and CAF-determinant genes 
(Figure 2C and 2D).
In parallel with the increase of senescence- and 
CAF-determinant gene expression, down-modulation of 
PDCD4 expression in HDFs resulted in induction of the 
“canonical” Notch/CSL targets HES1 and HEY1 (Figure 
2E), indicating that PDCD4 functions also as a negative 
co-regulator of these genes. Interestingly, up-regulation 
of these genes by both CSL and PDCD4 gene silencing 
was observed in HDFs and osteosarcoma (fibroblast-like) 
cell line Saos-2 cells, but not human primary keratinocytes 
(HKCs) or HeLa cells (Figure 2F). Only genes to which 
CSL is constitutively bound are induced when CSL levels 
decrease and differential binding of CSL to target genes 
can depend, among other things, on its expression levels, 
which can vary among cell types. Consistent with this 
possibility, immunoblot analysis showed consistently 
higher levels of CSL expression in multiple HDF strains 
and Saos-2 cells than in HKCs and HeLa cells, with an 
opposite pattern of PDCD4 expression (Figure 2G and 
2H).
Figure 2: PDCD4 as negative regulator of dermal fibroblast senescence and CAF activation. A. Clonogenecity assays. 
HDFs were infected with two shRNA PDCD4-silencing lentiviruses in parallel with empty vector control, followed by selection with 
puromycin for 48hrs, then plated under low density conditions on triplicated dishes (1000 cells per 60mm dish). Colony formation was 
measured by crystal violet staining after 14 days. b. Senescence Associated β-galactosidase activity (SA β-gal)  assay. HDFs infected with 
the PDCD4-silencing and control lentiviruses as in the previous panel were stained with SA β-gal at 7 days after infection. Representative 
images (left panel) and quantification of positive SA β-gal staining in ~100 cells (right panel) are shown. c. Parallel cultures of cells as in 
the previous panel were analyzed for expression of PDCD4 gene silencing and expression of the senescence-determinant CDKN1A gene by 
RT-PCR. D., E. HDFs were transfected with two different PDCD4-silencing siRNAs in parallel with scrambled siRNA control, followed, 
72hrs after transfection, by analysis of expression of the indicated genes by real time RT-PCR. Insert: Immunoblot analysis of HDFs plus/
minus siRNA-mediated silencing of PDCD4. F. HDFs, Saos-2 cells, human primary keratinocytes (HKCs) and HeLa cells were transfected 
with siRNAs for silencing of the CSL or PDCD4 genes in parallel with scrambled siRNA controls, followed by determination of  HES1 
expression by real time RT-PCR. G., H. Immunoblot analysis of CSL and PDCD4 expression in several HDF and HKC strains and Saos-2 
and HeLa cells as indicated, with tubulin as equal loading control.
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PDcD4 is a part of the csL repressive complex in 
controlling gene transcription
CSL has an intrinsic transcription repressive function 
and the expression of target genes to which it binds with 
high affinity is induced when levels of CSL decrease [19, 
20]. PDCD4 is devoid of intrinsic DNA binding activity. 
However, an attractive possibility is that PDCD4 may 
associate with CSL at specific target genes and affect their 
expression. Chromatin immunoprecipitation (ChIP) assay 
showed the binding of PDCD4 to the promoter regions of 
CAF genes, such as PTGS2 and IL6, at the same sites as 
CSL binds and also to the promoter region of canonical 
Notch target HES1 (Figure 3A). PDCD4 association to 
CSL binding region of HES1 was also found in Saos-2 
cells (Figure 3B). Importantly, we found that PDCD4 
binding to these genes was lost in CSL-silenced HDFs, 
indicating that it is CSL-dependent (Figure 3C). 
To further probe into the function of PDCD4, we 
assessed the consequences of its down-modulation on 
binding of CSL to its target genes. PDCD4 silencing did 
not change the binding of CSL to the promoter regions of 
IL6 and HES1 (Figure 3D), but resulted in increased levels 
of H3K27ac, a mark of activated chromatin (Figure 3E), 
consistent with PDCD4 being part of the CSL transcription 
repressive complex. 
In vivo role of PDcD4 in cAF activation
To assess whether the above findings are of in vivo 
significance, we started by assessing the level of PDCD4 
expression in stromal fibroblasts in premalignant or 
malignant lesions. Laser capture microdissection (LCM) 
analysis showed that PDCD4 was down-regulated in 
stromal fibroblasts underlying premalignant skin actinic 
keratosis (AKs) lesions relative to fibroblasts of adjacent 
unaffected skin (Figure 4A), and in stromal cells of in situ 
SCC relative to those of normal individuals (Figure 4B). 
A key feature of CAFs is their ability to enhance 
proliferation of neighboring cancer cells. Accordingly, 
HDFs plus/minus PDCD4 gene silencing were tested by 
intradermal tumorigenicity assays with a keratinocyte-
derived SCC cell line (SCC13). Tumor growth was 
enhanced when SCC13 cells were injected into mouse 
back skin with HDFs with PDCD4 gene silencing 
(Figure 5A). Tumors formed in the presence of HDFs 
Figure 3: Convergent binding of PDCD4 and CSL to common target genes. A. HDFs were assayed by ChIP with anti-CSL 
and PDCD4 antibodies in parallel with non-immune IgGs followed by real-time PCR of the indicated promoter regions of the PTGS2, 
IL6, and HES1 gene to which CSL was previously shown to bind [3]. Similar results were obtained in a second independent experiment 
(Supplementary Figure 1). b. Similar ChIP assays were performed with Saos-2 cells followed by PCR amplification of the indicated regions 
of the HES1 promoter. c. HDFs plus/minus shRNA-mediated CSL gene silencing were analyzed by ChIP with anti-PDCD4 antibodies in 
parallel with non-immune IgGs, followed by PCR of the indicated promoter regions of the HES1 and IL6 genes. D., E. HDFs plus/minus 
siRNA-mediated PDCD4 gene silencing were analyzed, 72hrs after siRNA transfection, by ChIP with anti-CSL (D) or anti-H3K27Ac (E) 
antibodies in parallel with non-immune IgGs followed by PCR of the indicated promoter regions of the HES1 and IL6 genes.
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with PDCD4 knockdown had higher cellularity and 
Ki67 proliferative index than with controls (Figure 5B). 
The same combination of cells was tested by alternative 
tumorigenicity assay based on injection into mouse ears. 
Histological analysis revealed that SCC13 cells forms 
tumors with higher cellularity when admixed with HDFs 
with PDCD4 knockdown, whereas tumors formed with 
control HDFs showed large empty or necrotic areas 
associated with the terminal differentiation cornification 
process (Figure 5C). In addition, greater positivity of the 
Ki67 proliferative index as well as the p63 proliferative 
marker was found in lesions formed with HDFs with 
PDCD4 silencing, while expression of the involucrin 
and loricrin differentiation marker was less (Figure 6A, 
6B and Supplementary Figure 2A), showing tumors 
formed with HDFs with PDCD4 silencing contain more 
undifferentiated tumor cells. Furthermore, expression of 
key CAF markers, such as αSMA, periostin, and tenascin 
C, was increased in tumors with HDFs with PDCD4 
silencing (Figure 6C and Supplementary Figure 2B). 
Thus, PDCD4 exerts a significant in vivo function 
in suppression of CAF activation, which parallels that of 
CSL.
DIscUssION
The CSL protein functions as a transcription 
regulator in concert with various co-repressors or co-
activators [5]. Besides the CSL associated proteins 
involved in canonical Notch-dependent control of 
transcription, there are others with distinct or separate 
functions. For instance, the CSL-interacting protein 
DDX5 plays a more peripheral role enhancing formation 
of the CSL co-activator complex [21, 22], while the 
pancreas-specific transcription factor 1 (Ptf1) interacts 
and functions together with CSL independently of 
Notch signaling [23]. The present findings indicate that 
PDCD4 is also connected with CSL function, in a cell 
type specific manner impinging on negative control of 
stromal fibroblasts to CAF activation. Interestingly, no 
direct binding was detected after over-expression of the 
two proteins in a heterologous system, which suggests 
that their interaction requires other intermediate proteins. 
However, the molecular mechanism by which PDCD4 
controls CSL repressive complex formation needs further 
investigation. SIRT1 and LSD1 proteins were recently 
found as a co-repressor component of CSL/Notch target 
genes with histone modifying activity [24] and it will be 
very interesting to assess whether PDCD4 is part of this 
new complex.
Figure 4: PDCD4 expression is down-regulated in stromal fibroblasts of premalignant and malignant keratinocitic 
lesions. A. Laser Capture Microdissection (LCM) and RT-qPCR analysis of PDCD4 expression in stromal cells underlying actinic keratosis 
(AK) and surrounding normal skin (NS) from the same patients, using β-actin normalization. The same samples were previously analyzed 
for CSL expression, ruling out leukocyte and endothelial cell contamination by RT-qPCR of corresponding markers [3]. n = 3, Two-tailed 
paired t-test. b. LCM and RT-PCR analysis of PDCD4 expression in stromal fibroblasts, identified by PDGFRα  immunofluorescence, of 
in situ SCC lesions versus normal skin from other individuals; mean +/-s.e.m. two-tailed unpaired t-test.
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Figure 5: PDCD4 depleted fibroblasts enhance tumorigenic behavior of keratinocyte-derived SCC cells. A. Weakly 
tumorigenic SCC13 cells were admixed with dermal fibroblasts freshly infected with a PDCD4 gene silencing lentivirus versus empty 
vector control (as in Figure 1) followed by intradermal injections into NOD/SCID mice. Mice were sacrificed at 3 weeks after injection and 
tumor volume was calculated using the formula V = (X2 x Y)/2. (X is the width and Y is the length of the tumor.) b. Tumors from the previous 
experiment were processed for histological examination and H&E staining (top panel) and immunofluorescence with antibody against the 
Ki67 proliferation marker with DAPI for nuclear staining (lower panel). Shown are representative images as well as a quantification of 
Ki67 positive nuclei using Image J. * p< 0.05, two-tailed t-test ,100μm. c. SCC13 cells were admixed with HDFs plus/minus PDCD4 gene 
silencing, as in the previous experiment, followed by parallel injections into mouse ears. At 3 weeks after injection, mice were sacrificed 
and ear lesions were processed for H&E staining. Bar, 400μm.
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Cancer-associated fibroblasts (CAFs) are well 
known to support tumor growth by secreting growth 
factors/cytokines [25, 26] and also by providing energy-
rich metabolites [27]. Many signaling pathways and 
transcription factors have been implicated in control 
of CAF gene expression [28], However, surprisingly 
little is known of the transcriptional changes involved 
in the early transition of normal fibroblasts into CAFs. 
Stromal alterations associated with cellular senescence 
and tissue aging can play an important role in the early 
stages of epithelial cancer development, with subsequent 
changes leading to cancer/stromal cell expansion [29]. 
Compromised Notch/CSL function is key at these 
early stages, leading to the concomitant induction of 
stromal fibroblast senescence and production of the 
“senescence messanging secretome” (SMS), a battery 
of tumor promoting cytokines, growth factors and 
matrix remodeling proteins that are a trademark of fully 
established CAFs [3]. Concurring with these findings, 
CSL is less expressed in stromal cells adjacent to skin 
premalignant lesions like actinic keratosis (AK) and in situ 
SCC relative to those of unaffected skin [3]. In parallel 
with CSL, we have shown here that PDCD4 expression is 
also decreased in stromal fibroblasts of these early lesions. 
Like with CSL, we have found that silencing of PDCD4 
was sufficient to induced fibroblast senescence and SMS 
production and, importantly, enhance squamous cell tumor 
formation. While PDCD4 has been extensively studied in 
cancer cells and tissues [9], there are very limited studies 
on PDCD4 functions in stromal cells, specifically one 
Figure 6: Dermal fibroblasts with PDCD4 gene silencing promote formation of SCC with higher proliferative index 
and suppressed differentiation. A. Immunofluorescence of ear lesions formed by SCC13 cells with HDFs plus/minus shRNA-
mediated silencing of PDCD4 with antibodies against Ki67 and Vimentin (upper panels) or Involucrin and p63 (lower panels). Shown are 
representative images as well as a quantification of Ki67, p63, and involucrin staining. Percentages of Ki67 positive nuclei in Vimentin 
negative SCC cells were quantified by Adobe Photoshop software using Lasso tool in three different fields from 3 ear pairs. p63 positive 
nuclei over total nuclei were quantified using Image J. * < 0.05, ** < 0.005, two-tailed t-test. Bar, 100μm. b. Immunofluorescence analysis 
of ear lesions formed by SCC13 cells with HDFs plus/minus shRNA-mediated silencing of PDCD4 with antibodies against Loricrin with 
DAPI for nuclear staining. Positive areas relative to entire lesion size (expressed as %) were quantified using Image J software. * < 0.05, two-
tailed t-test, Bar, 100μm. c. Immunofluorescence analysis of ear lesions formed by SCC13 cells with HDFs plus/minus shRNA-mediated 
silencing of PDCD4 with antibodies against Periostin (POSTN), Tenascin C (TNC), and α-Smooth muscle actin (ACTA2)with DAPI for 
nuclear staining. Shown are representative images as well as quantification of positive areas relative to entire lesion size (expressed as %) 
in 3 different fields from 3 ear pairs using Image J software. * < 0.05, two-tailed t-test, Bar, 100μm.
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implicating it in negative regulation of αSMA through 
unspecified mechanisms [18]. Besides associating 
with CSL, we have shown here that PDCD4 controls 
transcription of CAF effector genes as well as canonical 
Notch target genes in a fibroblast-specific manner with 
potentially important implications also for other systems 




HDFs and HKCs were obtained and cultured 
as previously described [2, 30]. Human skin samples 
for primary cell preparation were obtained from 
abdominoplasty procedures at Massachusetts General 
Hospital (MGH 2008-P-001742/2, Boston, Massachusetts, 
USA). Saos-2 and HeLa cell lines were purchased from 
the American Type Culture Collection (ATCC) and 
cultured in DMEM with 10% FBS. Human skin SCC13 
cells were originally reported in [31] and cultured in 
serum-free keratinocyte SFM medium. 
The lentiviral vectors encoding shRNA against 
PDCD4 (TRCN0000059081 and TRCN0000059078) 
were purchased from Openbiosystem. Lentiviruses 
were produced by cotransfection of HEK293 cells 
(Lipofectamine 2000, Invitrogen) with pLKO.1-shPDCD4 
and lentiviral package plasmids.
Co-immunoprecipitations and western blotting
Nuclear extracts were prepared using NE-PER 
nuclear and cytoplasmic extraction kit (Thermo Scientific) 
according to manufacturer’s instruction. 200 μg of nuclear 
fraction were incubated overnight at 4°C with PDCD4 
antibodies (Cell Signaling Technology) or control non-
immune IgGs. Dynabeads Protein G were incubated with 
the antigen-antibody complex for 4 hours at 4°C. Beads 
were washed three times with NP-40 buffer (20 mM Tris-
HCl buffer, pH 8 containing 150 mM NaCl, 1 % NP-40, 
1 % glycerol, and 2mM EDTA) and eluted in 50 ul of 2x 
SDS sample buffer at 95°C for 5 minutes and analysed by 
gel electrophoresis and immunoblotting.
For western blotting, cells were lysed using 
RIPA buffer (50mM Tris-HCl (pH 7.5), 150mM NaCl, 
1% NP-40, 0.5% sodium deoxycholate, 1mM EDTA) 
with protease inhibitor cocktail (Roche). Proteins were 
separated on NuPAGE 4-12 % Bis-Tris gels (Invitrogen) 
and transferred to a nitrocellulose membrane (Invitrogen). 
Antibodies specific to PDCD4 (Cell Signaling 
Technology), CSL (Cell Signaling Technology), and 
γ-tubulin (Sigma) were commercially obtained.
Immunofluorescence and proximity ligation assay
 Cells were fixed with 4% formaldehyde and 
permeabilized in 0.1% Triton X-100. After blocking with 
5% donkey serum in PBS, cells were incubated with 
primary antibody solution containing mouse monoclonal 
PDCD4 antibody (Santa Cruz Biotechnology) and rabbit 
monoclonal CSL antibody (Cell Signaling Technology). 
After washing, cells were incubated with goat anti-rabbit 
Alexa Fluor 488 and donkey anti-mouse Alexa Fluor 598 
antibodies (Invitrogen), then mounted with Vectashield 
mounting medium with DAPI (Vector Laboratories).
Proximity ligation assay was performed using 
Duolink PLA kit (Sigma) according to manufacturer’s 
protocol. Briefly, cells were fixed with 4% formaldehyde 
and permeabilized in 0.1% Triton X-100. After blocking 
with PLA blocking solution, cells were incubated with 
primary antibody solution containing PDCD4 and CSL 
antibodies. After washing with PLA wash buffer, cells 
were incubated with PLA probes, anti-rabbit PLUS, anti-
mouse MINUS, then washed, ligated, amplified by rolling 
circle amplification. Images were obtained with a Nikon 
Eclipse Ti confocal microscope. 
Senescence assay and clonogenicity
For clonogenicity assay, 1000 cells were plated in 
60mm dishes in triplicate and cultured for 14 days. The 
colonies were fixed with 70% ethanol and stained with 
1% crystal violet.
Senescence β-galactosidase (SA-β-Gal) activity 
assays was performed using senescence-galactosidase 
staining kit (Cell Signaling Technology) according to 
manufacturer’s protocol. For each strain, a minimum of 
100 cells was counted. 
siRNA transfection and realtime RT-PCR analysis
HDFs (4 × 105 cells) were plated in 60mm dishes 
24 hours prior to transfection and transfected with siRNA 
using Hiperfect (Qiagen). After 72 hours of transfection, 
cells were removed and total RNAs were isolated using 
RNeasy mini kit (Qiagen) according to the manufacturer’s 
protocol. RNAs were reverse-transcribed into cDNA 
using the iScriptTM cDNA synthesis kit (Bio-Rad), then 
analysed in triplicate with gene-specific primers and 
36β4 normalizaion. The primers used for realtime PCR 
analysis are listed in Supplementary Table 1. siRNAs for 
PDCD4 (Stealth RNAi HSS120545 and HSS120546) and 
CSL (Silencer Select siRNA s7252) were purchased from 
Invitrogen and Ambion. 
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Intradermal tumorigenicity assay
SCC13 cells (1 × 106 cells) were admixed with HDFs 
(5 × 105 cells) with shRNA-mediated silencing of PDCD4 
or control in 150 μl of growth factor-reduced matrigel (BD 
Bioscience) and intra-dermally injected into the back skin 
of 6-week-old NOD/SCID mice (Taconic Farms Inc.) as 
previously described [30]. For the ear injection, SCC13 
cells (1 × 105 cells) were admixed with equal numbers 
of HDFs with shRNA-mediated silencing of PDCD4 or 
control. Cells were resuspended in 3 μl of Hanks’ balanced 
salt solution and then injected intradermally into the left 
and right tip of the ear dermis of 10-week-old NOD/SCID 
mice using a Hamilton microsyringe fitted with 33 gauge 
needle as performed in [3]. Mice were sacrificed 3 weeks 
after injection and tumors were removed for analysis. 
Tissue immunofluorescence was performed as 
before [2, 3]. Anti- ki67 antibody, anti-Vimentin antibody 
(Abcam), anti-p63 antibody (Santa Cruz Biotechnology), 
anti-Involucrin antibody (Sigma), anti-Periostin antibody 
(Abcam), anti-Tenascin C antibody (Santa Cruz 
Biotechnology), and anti-αSMA antibody (Santa Cruz 
Biotechnology) were used. Quantification of all images of 
tissue immunofluorescence staining was performed using 
ImageJ and Adobe Photoshop software.
All animal studies were performed following 
the approved Institutional animal protocol procedure 
(IACUC-MGH).
Laser capture microdissection (LcM)
LCM was performed as described previously [3]. 
Briefly, laser-captured cells from paraffin sections were 
collected using an Arcturus XT microdissection system 
(Applied Biosystems) and RNAs were purified by RNeasy 
FFEP kit (Qiagen). For immunofluorescence-guided 
LCM, frozen blocks of normal skin and in situ SCCs were 
freshly cut, immediately fixed and blocked. Sections were 
incubated with a mixture of fluorescein isothiocyanate 
(FITC)-conjugated antibodies against PDGFRα (Santa 
Cruz Biotechnology) and propidium iodide. The air-dried 
sections were then used for fluorescence-guided LCM 
using an Arcturus XT microdissection system as before. 
RNA samples were analysed in triplicate with gene-
specific primers.
chromatin immunoprecipitation (chIP)
ChIP assays were performed as previously described 
[3]. Briefly, cells were cross-linked with 1% formaldehyde 
and chromatin fragmentation was done by sonication 
using a Bioruptor (Cosmo-Bio Diagenode). Fragmented 
chromatins were diluted 10-fold with ChIP dilution buffer 
(0.01% SDS, 1.1% Triton X-100, 2mM EDTA, 55mM 
Tris-HCl, pH 7.9, 167mM NaCl) and immunoprecipitated 
with PDCD4 antibody, CSL antibody or H3K27Ac 
antibody (Cell Signaling Technology). The primers used 
for realtime PCR analysis are listed in Supplementary 
Table 1. 
statistics
Data are presented as mean ± standard deviation 
(s.d.), mean ± standard error of the mean (s.e.m.). All 
realtime RT-PCR samples were tested in triplicate, and 
statistical significance of the results was assessed by two-
tailed unpaired or paired t-test. P-value of < 0.05 was 
considered statistically significant.
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